Allergic Treatment Market



An allergy is an ailment due to hypersensitivity of the immune system because of the typically harmless substances (allergens) in the environment. Allergens can be dust mite, mould, grass pollen, milk, soy, wheat, egg and others. These allergens can cause many allergic disease conditions, including hay fever or allergic rhinitis, asthma, atopic dermatitis, and others. The primary symptoms of allergic reactions include itching in the nose, sneezing, stuffy nose (congestion), teary eyes, and many others. Also, food allergies can cause symptoms such as vomiting, diarrhea, or problems in respiration.

The primary vital factors that drive the global allergy treatment market include a significant increase in the allergic disease’s prevalence, rise in over-the-counter drugs for allergy treatment, and an increase in self-medication.

Allergy treatment market based on the type

The allergy treatment market based on type is divided into eye allergy, food allergy, skin allergy, asthma, rhinitis, and several others. The rhinitis allergy segment was the highest in the market in 2017 and is expected to maintain its influence throughout the forecast period. This was credited due to the increase in the allergic rhinitis prevalence worldwide.

Allergy treatment market based on treatment

The allergy treatment market based on treatment is categorised into anti-allergy drugs and immunotherapy. The anti-allergy drugs segment credited for the highest revenue in 2017and is anticipated to maintain its influence in the forecast period.

Many companies are working for allergy treatment market, which includes:- GlaxoSmithKline, ALK-Abelló A/S, Sallergenes Greer, Allergy Therapeutics, Sanofi SA, Johnson & Johnson, Merck Co. In, Merck KGaA, F. Hoffmann-La Roche AG, and Allergan plc.



Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more